Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 3/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12107122 | 0.96 | HSD17B1 (0.50) | HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL28527720 | 0.83 | HSD17B1 (0.62) | HSD17B1HSD17B2CYP3A4CYP2C19 | |
| SCHEMBL28529085 | 0.81 | HSD17B1 (0.47) | HSD17B1HSD17B2CYP3A4CYP2C19MEN1 | |
| SCHEMBL3479599 | 0.81 | TSHR (0.56) | TSHRMGLL | |
| 2-Thiophenenecarboxaldehyde SCHEMBL28159808 | 0.80 | DPP4 (0.41) | HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL28606077 | 0.79 | HDAC3 (0.47) | HSD17B1HSD17B2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL2558370 | 0.79 | HSD17B1 (0.42) | HSD17B1HSD17B2TSHRCA2 | |
| SCHEMBL2556281 | 0.79 | HSD17B1 (0.49) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2556652 | 0.79 | TSHR (0.52) | HSD17B1RAB9AMEN1POLBKMT2A | |
| SCHEMBL28527091 | 0.79 | CYP2A6 (0.56) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102715-B1 | ROS-responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2024-10-01 | — | — | US | claimed |
| US-11179335-B1 | ROS-responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2021-11-23 | — | — | US | claimed |
| US-10517823-B1 | ROS—responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2019-12-31 | — | — | US | claimed |
| CN-113788790-B | Aromatic heterocyclic amide derivative and application thereof | 华东理工大学 | 2025-02-18 | — | — | CN | disclosed |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-12102715-B1 | ROS-responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2024-10-01 | — | — | US | disclosed |
| WO-2024003151-A1 | CHEMICAL SYNTHESIS PLATFORM | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2024-01-04 | — | — | WO | disclosed |
| CN-110997648-B | Condensed ring compound | 东曹株式会社 | 2023-12-19 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220202772-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2022-06-30 | — | — | US | disclosed |
| US-11318097-B1 | ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages | VERILY LIFE SCIENCES LLC (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1784400-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1723116-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co. KGaA (DE) | 2006-11-22 | — | — | EP | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
| WO-2006053748-A1 | SUBSTITUTED [(PHENYLETHANOYL)AMINO] BENZAMIDES AND THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AND CARDIO-VASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006023462-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-08 | — | — | US | disclosed |
| JP-2004059457-A | METHOD FOR PRODUCING (THIOPHENE/PHENYLENE)COOLIGOMERS | SUMITOMO SEIKA CHEM CO LTD | 2004-02-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202772-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS | RACK1, RRBP1, RPL30 | HSD17B1 4125/4885HSD17B2 4194/4885CYP2E1 4309/4885 |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | HSD17B1 441/4885HSD17B2 447/4885CYP2E1 2026/4885 |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | HSD17B1 19/4885HSD17B2 18/4885CYP2E1 370/4885 |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | GRM5, GRIK5, GRIN2C | HSD17B1 3585/4885HSD17B2 3613/4885CYP2E1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.